IFNA2 and plasma cell myeloma: In spite of being discovered for their anti-viral activities, IFN-α2a and IFN-α2b have been used as anticancer therapeutic agents across multiple cancer types, including hairy cell leukemia, chronic myelogenous leukemia (CML) (104), AIDS-related Kaposi's sarcoma, follicular lymphoma, multiple myeloma, melanoma, condyloma acuminate, hepatocellular carcinoma (HCC), and cervical intraepithelial neoplasms (105, 106).